Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

14.04.2025

1 Am J Gastroenterol
1 Am J Pathol
1 Ann Intern Med
2 BMC Cancer
11 BMC Gastroenterol
2 Br J Surg
1 Cancer Res
4 Clin Res Hepatol Gastroenterol
7 Dig Dis Sci
2 Endoscopy
1 Eur Radiol
3 Gut
8 Hepatology
1 J Comput Assist Tomogr
1 J Gastroenterol
3 J Gastroenterol Hepatol
1 J Hepatol
1 Minerva Gastroenterol (Torino)
4 Oncogene
1 Radiologia (Engl Ed)
2 Radiology
2 Semin Liver Dis


    Am J Gastroenterol

  1. MOON AM, Lupu GV, Green EW, Deutsch-Link S, et al
    Rural-urban disparities in hepatocellular carcinoma deaths are driven by hepatitis C-related HCC.
    Am J Gastroenterol. 2025 Apr 11. doi: 10.14309/ajg.0000000000003487.
    >> Share


    Am J Pathol

  2. XU L, Zhao Y, Yang Y, Qi E, et al
    Constitutive hepatic mTORC1 activation aggravates alcohol-induced liver injury via endoplasmic reticulum stress-mediated ferroptosis.
    Am J Pathol. 2025 Apr 7:S0002-9440(25)00106-3. doi: 10.1016/j.ajpath.2025.
    >> Share


    Ann Intern Med

  3. CINTOSUN A, Jamal I, Samnani S, Song YN, et al
    Gastroenterology/Hepatology: What You May Have Missed in 2024.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00959.
    >> Share


    BMC Cancer

  4. CAI X, Guo W, Wu F, Xu W, et al
    Epigenetic-modification associated hnRNPA3 acts as a prognostic biomarker and promotes malignant progression of HCC.
    BMC Cancer. 2025;25:661.
    >> Share

  5. ZHANG J, Lan Z, Zhu K, Yu S, et al
    Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B.
    BMC Cancer. 2025;25:635.
    >> Share


    BMC Gastroenterol

  6. LI Y, Feng Z, Liang C, Lu S, et al
    The double-edged sword: impact of antibiotic use on immunotherapy efficacy in advanced hepatocellular carcinoma.
    BMC Gastroenterol. 2025;25:221.
    >> Share

  7. WANG QQ, Zhang N, Xu X, Lv SA, et al
    The role of Triglyceride Glucose-Waist Circumference (TyG_WC) in predicting metabolic dysfunction-associated steatotic liver disease among individuals with hyperuricemia.
    BMC Gastroenterol. 2025;25:220.
    >> Share

  8. ASHRAF T, Abunada O, Seerani N, Ali K, et al
    The role of Seladelpar in primary biliary cholangitis: a systematic review and meta-analysis.
    BMC Gastroenterol. 2025;25:224.
    >> Share

  9. LI S, Zhang Y, Zhou F, Xu S, et al
    Iceball growth 3D simulation model based on finite element method for hepatic cryoablation planning.
    BMC Gastroenterol. 2025;25:227.
    >> Share

  10. XIA C, Liu Y, Qing X
    Burden of gastrointestinal cancers in Asia, 1990-2019.
    BMC Gastroenterol. 2025;25:232.
    >> Share

  11. WANG H, Ye J, Chen Y, Sun Y, et al
    High sensitivity C-reactive protein implicates heterogeneous metabolic phenotypes and severity in metabolic dysfunction associated-steatotic liver disease.
    BMC Gastroenterol. 2025;25:231.
    >> Share

  12. SAEEDIAN B, Babajani N, Bagheri T, Shirmard FO, et al
    Efficacy and safety of PPAR agonists in primary biliary cholangitis: a systematic review and meta-analysis of Randomized Controlled Trials.
    BMC Gastroenterol. 2025;25:230.
    >> Share

  13. YU C, He S, Peng N, Kuang M, et al
    The fasting plasma glucose to high-density lipoprotein cholesterol ratio: a novel index for identifying NAFLD.
    BMC Gastroenterol. 2025;25:236.
    >> Share

  14. CHEN R, Liu Y, Ma L, Zhang W, et al
    Correlation and consistency analysis between various indirect portal pressure gradients and actual portal pressure gradient.
    BMC Gastroenterol. 2025;25:241.
    >> Share

  15. XIE C, Chen X, Zhang J, Jiang X, et al
    Metabolic score for visceral fat is correlated with all-cause and cardiovascular mortality among individuals with non-alcoholic fatty liver disease.
    BMC Gastroenterol. 2025;25:238.
    >> Share

  16. SHI J, Cui J, Zheng T, Han X, et al
    Comparative effects of aerobic and resistance exercise on bile acid profiles and liver function in patients with non-alcoholic fatty liver disease.
    BMC Gastroenterol. 2025;25:239.
    >> Share


    Br J Surg

  17. KAWASHIMA J, Akabane M, Khalil M, Woldesenbet S, et al
    Tumour burden predicts outcomes after curative resection of multifocal intrahepatic cholangiocarcinoma.
    Br J Surg. 2025;112:znaf050.
    >> Share

  18. SOREIDE K
    Resection of multifocal intrahepatic cholangiocarcinoma.
    Br J Surg. 2025;112:znaf048.
    >> Share


    Cancer Res

  19. LEE TKW, Ma S
    PROX1: a key regulator of hepatocyte identity and tumorigenesis.
    Cancer Res. 2025 Mar 31. doi: 10.1158/0008-5472.CAN-25-1377.
    >> Share


    Clin Res Hepatol Gastroenterol

  20. MAHDIZADEH F, Sobhi P, Banaei S
    A class of MicroRNAs as diagnostic biomarkers and therapeutic strategies in non-alcoholic fatty liver disease: A review.
    Clin Res Hepatol Gastroenterol. 2025;49:102547.
    >> Share

  21. YANG T, Wang SY
    Integrating transcriptome and metabolomics analyses of hepatocellular carcinoma to discover novel biomarkers and drug targets.
    Clin Res Hepatol Gastroenterol. 2025;49:102546.
    >> Share

  22. LIU Z, Yang X, Jiang H, Xie R, et al
    Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis.
    Clin Res Hepatol Gastroenterol. 2025 Feb 19:102553.
    >> Share

  23. LANTHIER N, Spahr L
    Macrophage therapy and liver regeneration: Results and perspectives.
    Clin Res Hepatol Gastroenterol. 2025;49:102569.
    >> Share


    Dig Dis Sci

  24. KEHAR M, Huerta-Saenz L, Strain J, Kawesa S, et al
    Challenges in Promoting Physical Activity for Managing MASLD in Canadian Children: Insights and Barriers.
    Dig Dis Sci. 2025;70:1368-1374.
    >> Share

  25. AZIZ S, Hamid A, Shaikh A, Mansoor R, et al
    Unveiling Disparities in Heart Failure and Cirrhosis Related Mortality: CDC WONDER 1999 to 2020.
    Dig Dis Sci. 2025 Apr 10. doi: 10.1007/s10620-025-08970.
    >> Share

  26. ZHU T, Wan X
    Hepatic Subcapsular Hematoma Induced by Metastatic Tumors.
    Dig Dis Sci. 2025 Apr 9. doi: 10.1007/s10620-025-09036.
    >> Share

  27. TAO T, Lv L, Chen J, He Y, et al
    Identification of Crosstalk Genes Between Primary Sjogren's Syndrome and Primary Biliary Cirrhosis by Transcriptome Analysis.
    Dig Dis Sci. 2025 Apr 8. doi: 10.1007/s10620-025-08917.
    >> Share

  28. SINGAL AK
    Hepatocellular Carcinoma in Acute Porphyria: Incidence and Risk Factors.
    Dig Dis Sci. 2025 Apr 2. doi: 10.1007/s10620-025-09003.
    >> Share

  29. LEUNG CW, Tapper EB
    Food Insecurity Is Increasing and Is More Common Among Persons with Chronic Liver Disease.
    Dig Dis Sci. 2025;70:1360-1367.
    >> Share

  30. SOGBE M, Hummer B, Stine JG, Lizaola-Mayo B, et al
    Advanced Liver Fibrosis Impairs Cardiorespiratory Fitness in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Dig Dis Sci. 2025;70:1530-1539.
    >> Share


    Endoscopy

  31. SASSE A, Steuber BC, Ellenrieder V, Petzold G, et al
    Successful delayed endoscopic management of dislocated hepaticogastrostomy stent with self-expanding metal stent and esophageal perforation closure.
    Endoscopy. 2025;57.
    >> Share

  32. INOUE T, Kitano R, Kitada T, Sakamoto K, et al
    Endoscopic ultrasound-guided antegrade treatment using a novel nonslip short-length balloon catheter for hepaticojejunostomy anastomotic stricture.
    Endoscopy. 2025;57.
    >> Share


    Eur Radiol

  33. SONG W, Xu Y, Zhou J, Yu J, et al
    Predicting postresection outcomes in solitary small hepatocellular carcinoma via pretreatment MR imaging features: subgroup analysis according to alpha-fetoprotein expression.
    Eur Radiol. 2025 Apr 11. doi: 10.1007/s00330-025-11558.
    >> Share


    Gut

  34. CELSA C, Pennisi G, Tulone A, Ciancimino G, et al
    Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies.
    Gut. 2025;74:815-824.
    >> Share

  35. JIA Q, Sun X, Li H, Guo J, et al
    Perturbation of mRNA splicing in liver cancer: insights, opportunities and challenges.
    Gut. 2025;74:840-852.
    >> Share

  36. MACCIONI L, Guan Y, Kim M, Parra MA, et al
    Opposite regulation of intestinal and intrahepatic CD8(+) T cells controls alcohol-associated liver disease progression.
    Gut. 2025 Apr 8:gutjnl-2024-334412. doi: 10.1136/gutjnl-2024-334412.
    >> Share


    Hepatology

  37. KUREBAYASHI Y, Sakamoto M
    Macrotrabecular hepatocellular carcinoma: Unique immunovascular characteristics.
    Hepatology. 2025 Apr 1. doi: 10.1097/HEP.0000000000001339.
    >> Share

  38. WANG B, Hsu SH, Wang X, Kutay H, et al
    Erratum: Reciprocal regulation of microRNA-122 and c-Myc in hepatocellular cancer: Role of E2F1 and transcription factor dimerization partner 2.
    Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001261.
    >> Share

  39. LAI JC, Lok AS
    Accurate prediction of hepatocellular carcinoma risk in patients with chronic HBV infection: HBeAg status and HBsAg level matter.
    Hepatology. 2025 Apr 3. doi: 10.1097/HEP.0000000000001345.
    >> Share

  40. YANG LX, Gao Q, Shi JY, Wang ZC, et al
    Erratum: Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition.
    Hepatology. 2025 Apr 7. doi: 10.1097/HEP.0000000000001274.
    >> Share

  41. BRUNO BJ, Weavil JC, Ogle J, Chidambaram N, et al
    Reply: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001348.
    >> Share

  42. TANTAI X, Li L, Dai S
    Letter to the editor: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001349.
    >> Share

  43. ROCCARINA D, Saltini D, Senzolo M, Nardelli S, et al
    Reply: Post-TIPS hemodynamic target adherence fails to improve outcomes in cirrhotic patients.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001350.
    >> Share

  44. TANTAI X, Li L, Dai S
    Letter to the editor: Considerations on the use of LPCN 1148 in cirrhotic patients with sarcopenia.
    Hepatology. 2025 Apr 8. doi: 10.1097/HEP.0000000000001347.
    >> Share


    J Comput Assist Tomogr

  45. DONG M, Chen F, Huang W, Liao Y, et al
    Multiregional Radiomics to Predict Microvascular Invasion in Hepatocellular Carcinoma Using Multisequence MRI.
    J Comput Assist Tomogr. 2025 Mar 18. doi: 10.1097/RCT.0000000000001752.
    >> Share


    J Gastroenterol

  46. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    >> Share


    J Gastroenterol Hepatol


  47. Correction to "PLK2 Inhibited Oxidative Stress and Ameliorated Hepatic Ischemia-Reperfusion Injury Through Phosphorylating GSK3beta".
    J Gastroenterol Hepatol. 2025 Apr 10. doi: 10.1111/jgh.16966.
    >> Share

  48. FILHO VOC, Passos PRC
    PCED1A as a Predictive Biomarker for Immunotherapy and Anti-Angiogenic Treatment in Hepatocellular and Colorectal Cancer.
    J Gastroenterol Hepatol. 2025 Apr 9. doi: 10.1111/jgh.16969.
    >> Share

  49. LI J, Zhao Y, Wang Z, Ma A, et al
    Irisin Alleviates Impaired Mitochondrial Fusion via Enhancing PKA/SIRT3/mTOR Pathway in Hepatic Steatosis.
    J Gastroenterol Hepatol. 2025 Apr 2. doi: 10.1111/jgh.16950.
    >> Share


    J Hepatol

  50. ZHOU S, Zhang L, You Y, Yu K, et al
    eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma.
    J Hepatol. 2025 Mar 26:S0168-8278(25)00206-5. doi: 10.1016/j.jhep.2025.
    >> Share


    Minerva Gastroenterol (Torino)

  51. LI CAVOLI TV, Curto A, Lynch EN, Galli A, et al
    Disease-specific non-invasive assessment of liver fibrosis and portal hypertension in 2024.
    Minerva Gastroenterol (Torino). 2025 Mar 31. doi: 10.23736/S2724-5985.25.03845.
    >> Share


    Oncogene

  52. JIANG S, Jiang L, Xu Y, Ma Y, et al
    USP5 deubiquitinates and stabilizes IMPDH2, to promote hepatocellular carcinoma progression.
    Oncogene. 2025 Mar 31. doi: 10.1038/s41388-025-03355.
    >> Share

  53. ZHANG GP, Song ZB, Chen DH, Yu Y, et al
    Syntaxin-6 mediated autophagy confers lenvatinib resistance in hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03371.
    >> Share

  54. LI D, Gao Z, Zhang Z, Chen H, et al
    Suprabasin promotes gastric cancer liver metastasis via hepatic stellate cells-mediated EGF/CCL2/JAK2 intercellular signaling pathways.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03370.
    >> Share

  55. ZHANG H, Kong X, Qu H, Gao Y, et al
    MYCBP2-mediated HNF4alpha ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.
    Oncogene. 2025 Apr 3. doi: 10.1038/s41388-025-03373.
    >> Share


    Radiologia (Engl Ed)

  56. PERIS ALVA H, Cano Rodriguez C, Bosch Barragan F, Framis Utset A, et al
    New-onset hepatic lesions in oncological patients: A challenging diagnosis.
    Radiologia (Engl Ed). 2025;67:191-201.
    >> Share


    Radiology

  57. QIU C
    US Markers for Differentiating Hepatic Inflammation in Chronic Liver Disease: Still a Long Way to Go.
    Radiology. 2025;315:e242559.
    >> Share

  58. GUO X, Zhou Y
    Agenesis of the Intrahepatic Inferior Vena Cava with Pulmonary Venous Fistula.
    Radiology. 2025;315:e242069.
    >> Share


    Semin Liver Dis

  59. RAMIREZ-QUESADA W, Alvarado-Tapias E, Shalaby S, Hernandez-Gea V, et al
    Recompensation in Cirrhosis: Biomarkers and Strategies.
    Semin Liver Dis. 2025 Apr 3. doi: 10.1055/a-2542-9930.
    >> Share

  60. SONG Y, Yang X, Yu C
    Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research.
    Semin Liver Dis. 2025 Apr 1. doi: 10.1055/a-2570-3330.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016